Integra Lifesciences vs Integer
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Integra Lifesciences and Integer side by side, using each one’s latest annual report. Here is what stands out:
- Integer is the larger business, with $1.9B of revenue in fiscal 2025 against $1.6B for Integra Lifesciences.
- Integer grew revenue faster (8.0%, against 1.5%).
- Integer kept more of each dollar of sales as operating profit (11.9% operating margin, against −30.2%).
- Integer turned more of its sales into free cash flow (5.7% FCF margin, against −1.9%).
- Integer earned a higher return on the capital invested in it (6.6%, against −22.0%).
- Investors pay more for each dollar of Integra Lifesciences’s earnings: a P/E of 70.1x against 34.7x for Integer.
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
Integra Lifesciences
IART
2/10
Gross marginShare count change
Integer
ITGR
8/10
Revenue growth5-year growthOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-score
Side by side
Best in the row
| Latest fiscal year | IART FY25 | ITGR FY25 |
|---|---|---|
| Size | ||
| Market cap | $936M | $4.3B |
| Revenue | $1.6B | $1.9B |
| Free cash flow | −$31.1M | $105M |
| Net income | −$517M | $103M |
| Growth | ||
| Revenue growth | 1.5% | 8.0% |
| 5-year growth | 3.6% | 11.6% |
| Share count change | −0.4% | −0.2% |
| Profitability | ||
| Gross margin | 50.9% | 27.0% |
| Operating margin | −30.2% | 11.9% |
| Net margin | −31.6% | 5.6% |
| FCF margin | −1.9% | 5.7% |
| Return on capital | −22.0% | 6.6% |
| Return on equity | −39.9% | 6.1% |
| Balance sheet | ||
| Net debt | $463M | $1.2B |
| Net debt / EBITDA | — | 3.4x |
| Dividends and buybacks | $0.2M | $50.0M |
| Valuation & quality | ||
| P/E | 70.1x | 34.7x |
| Piotroski F-score | 5 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.